Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330343 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| SCHEMBL28429589 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| SCHEMBL2378732 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| SCHEMBL2379232 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| Hydrochloric Acid SCHEMBL2378728 | 0.99 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| Hydrochloric Acid SCHEMBL22613316 | 0.99 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| Hydrochloric Acid SCHEMBL2379142 | 0.99 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| Hydrochloric Acid SCHEMBL2379229 | 0.99 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| Hydrochloric Acid SCHEMBL28401379 | 0.99 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| SCHEMBL16653836 | 0.90 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230057166-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | ACLARIS THERAPEUTICS, INC. | 2022-08-23 | — | — | US | disclosed |
| CN-113727975-A | Substituted pyrrolopyridines as JAK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-112739420-A | Phenoxy-pyridyl-pyrimidine compounds and methods of use | 基因泰克公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | GENENTECH, INC. (US) | 2021-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057166-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | XBP1, ERN1, ESR2 | SMN1; SMN2 1892/4885CYP2C19 1981/4885NPC1 1937/4885 |
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | SMN1; SMN2 4883/4885CYP2C19 1469/4885NPC1 3601/4885 |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | XBP1, ERN1, ATF4 | SMN1; SMN2 379/4885CYP2C19 4056/4885NPC1 283/4885 |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | XBP1, ERN1, ESR2 | SMN1; SMN2 1892/4885CYP2C19 1981/4885NPC1 1937/4885 |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | JAK1, JAK3, JAK2 | SMN1; SMN2 4883/4885CYP2C19 1469/4885NPC1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.